SCYNEXIS

$7.73
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.04 (-0.51%) Today
$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

You can buy or sell SCYNEXIS and other stocks, options, and ETFs commission-free!

About SCYX

SCYNEXIS, Inc. Common Stock, also called SCYNEXIS, is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections.

CEO
Marco Taglietti
Employees
38
Headquarters
Jersey City, New Jersey
Founded
1999
Market Cap
168.44M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
247.32K
High Today
$7.88
Low Today
$7.65
Open Price
$7.88
Volume
299.78K
52 Week High
$10.40
52 Week Low
$4.20

SCYX Earnings

-$3.78
-$2.52
-$1.26
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 10, Pre-Market

You May Also Like

UZB
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure